Search
for
Sort by
Research 31–60 of 1000+
- Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
- A Neutralizing Prolactin Receptor Antibody Whose In Vivo Application Mimics the Phenotype of Female Prolactin Receptor-Deficient Mice
- Preparation of a highly specific single chain variable fragment antibody targeting miroestrol and its application in quality control of <i>Pueraria candollei</i> by enzyme‐linked immunosorbent assay
- Data from Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
- Data from Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
- Treatment of Alopecia Areata with Anti-Interferon-γ Antibodies
- Acidic and basic hair/nail ("hard") keratins: their colocalization in upper cortical and cuticle cells of the human hair follicle and their relationship to "soft" keratins.
- The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside
- Targeting the Wnt pathways for therapies
- Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
- Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors
- Aberrant expression of epidermal growth factor receptor in aural cholesteatoma
- Trichohyalin: Presence in the Granular Layer and Stratum Corneum of Normal Human Epidermis
- Dupilumab and alopecia: A Janus effect
- Alopecia Areata after Omalizumab Treatment for Chronic Spontaneous Urticaria
- Evidence for multiple, developmentally regulated isoforms of Ptprq on hair cells of the inner ear
- Immunomodulators in the treatment of cutaneous lymphoma
- Recalcitrant lichen planopilaris and frontal fibrosing alopecia responding to tildrakizumab
- The expression of equine keratins K42 and K124 is restricted to the hoof epidermal lamellae of Equus caballus
- Alopecia areata after mogamulizumab treatment
- Challenging Regional Psoriasis and Ustekinumab Biotherapy: Impact of the Patterns of Disease
- Cutaneous lesions and clinical outcomes in five cats after frunevetmab injections
- A Potential Role for IL-4 and IL-13 in an Alopecia Areata–Like Phenotype: A Clinical Perspective
- Dupilumab in the treatment of severe atopic dermatitis refractory to systemic immunosuppression: case report
- Hypertrichosis of the pinnae in a patient using panitumumab
- Treatment of chronic alopecia areata with tildrakizumab: an open‐label pilot study
- Drug-induced scarring and permanent alopecia
- Reversing Gray Hair: Inspiring the Development of New Therapies Through Research on Hair Pigmentation and Repigmentation Progress
- ANIFROLUMAB IN THE MANAGEMENT OF LUPUS HEADACHES: A CASE REPORT
- LB793 A phase 1, open-Label, single ascending dose study in healthy subjects of the safety, tolerability and pharmacokinetics of ASLAN004, a novel IgG anti-IL-13 receptor alpha 1 Inhibitor